DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Exelon (Rivastigmine Tartrate) - Summary

 
 



EXELON SUMMARY

Exelon

Exelon® (rivastigmine tartrate) is a reversible cholinesterase inhibitor.

Exelon® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.


See all Exelon indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Exelon (Rivastigmine)

UB researchers corroborate the neuroprotective effects of Sirtuin 1 activation on mice with Alzheimer's disease
Source: Neurology / Neuroscience News From Medical News Today [2014.09.19]
A study coordinated by the University of Barcelona (UB) has described a mechanism that plays a key role in the evolution of Alzheimer's disease.

In mouse model of Alzheimer's disease, targeted immune booster removes toxic proteins
Source: Immune System / Vaccines News From Medical News Today [2014.09.11]
Alzheimer's disease experts at NYU Langone Medical Center and elsewhere are reporting success in specifically harnessing a mouse's immune system to attack and remove the buildup of toxic proteins in...

Memory and Alzheimer's disease
Source: Schizophrenia News From Medical News Today [2014.09.03]
Research by Dr. Sylvain Williams shows that the flow of activity in the hippocampus, a brain region essential for memory, is actually bidirectional, rather than just unidirectionalA study just...

Protein implicated in Alzheimer's disease has important treatment potential in genetic form of epilepsy
Source: Autism News From Medical News Today [2014.08.16]
Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe...

Alzheimer's Disease
Source: MedicineNet Encephalitis and Meningitis Specialty [2014.08.05]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 2:43:00 PM
Last Editorial Review: 8/5/2014 2:43:52 PM

more news >>

Published Studies Related to Exelon (Rivastigmine)

Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. [2012]
disease in whom conventional therapy failed... CONCLUSIONS: The results of this pilot trial need to be confirmed by further

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2011.12]
OBJECTIVES: The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline... CONCLUSIONS: Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population. Copyright (c) 2010 John Wiley & Sons, Ltd. Copyright (c) 2010 John Wiley & Sons, Ltd.

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
CONCLUSION: There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. [2011.04]
OBJECTIVE: In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items... CONCLUSIONS: These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright (c) 2010 John Wiley & Sons, Ltd.

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. [2011.02]
BACKGROUND: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD)... CONCLUSION: Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.

more studies >>

Clinical Trials Related to Exelon (Rivastigmine)

A Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelon�) Administration in Young Healthy Male Volunteers [Not yet recruiting]
Rivastigmine is a carbamate, approved by the FDA for the treatment of mild to moderate dementia associated with Alzheimer's and Parkinson's diseases. Studies conducted in the Israel Institute of Biological Research (IIBR) have yielded encouraging results in utilizing rivastigmine pre-treatment as an alternative to pyridostigmine in partially protecting against organophosphate poisoning, particularly protecting the central nervous system.

The target population for this indication may consist of otherwise healthy people (e. g. soldiers). Although the treatment regimen has not been established yet it is assumed, based on animal experiments, that rivastigmine is likely to be administered in repeated doses. In this setting, further evaluation of the drug's effects and pharmacokinetics in young healthy subjects is warranted.

The objectives of this study are: 1) To assess the safety and tolerability of repeated rivastigmine administration (1. 5 mg and 3 mg) in young healthy male volunteers; 2) To determine the pharmacokinetic profile of rivastigmine (1. 5 mg and 3 mg) following a single and multiple dose administrations; 3) To assess the extent of blood ChE inhibition following a single and multiple administrations of rivastigmine and 4) To correlate physiological and behavioral effects with blood rivastigmine concentrations and blood ChE inhibition in these subjects.

This double-blind, placebo-controlled study will be divided in 3 identical periods, preceded with a two-day initial training in performing cognitive performance tests. Each period will consist of in-house confinement for 5 days in which rivastigmine will be administered 5 times at an interval of 12 hours. During each period, each subject will receive either rivastigmine 1. 5 mg X 5, or either rivastigmine 3. 0 mg X 5 or placebo X 5. The treatment in each period will be randomly assigned in a crossover manner. Rivastigmine pharmacokinetics will and acetylcholinesterase inhibition will be assessed after the first and the last dose of each period and will be correlated with physiological and cognitive parameters: performance tests, visual functions, peak airway flow, saliva production (sialometry) and vital signs.

The emergence of adverse events will be monitored throughout the study

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients [Recruiting]
The purpose of this study is to determine whether a exercise program when combined with rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone would improve quality of life, ability to perform activities of daily living (ADL) and cognition in patients with Alzheimer's disease.

Hypothesis:

Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug treatment to improve quality of life of alzheimer's disease patients.

H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug treatment to improve quality of life of alzheimer's disease patients, with an expectative of 15% of improvement in the quality of life scale measurement

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence [Recruiting]
The purpose of this study is to determine the safety and effects of rivastigmine and huperzine A (HupA), potential treatments for cocaine abuse, when used before experimental administration of cocaine, on a number of physical and psychological measures.

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients [Recruiting]
The investigators plan to see what factors can influence the durability of Exelon patch treatment in Korean patients with Alzheimer's disease.

Based on these results, the investigators will find the ways to maximize the effect and durability of Exelon patch on Korean patients with Alzheimer's disease.

After finishing this study, the investigators are going to present the study results at the international and national academic meetings or conferences.

Also the investigators expect that they can publish the result in a journal of in the field of neurology or dementia till the winter of 2010.

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia [Recruiting]
This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over conventional oral therapies: smooth drug delivery with reduced side effects;(2) encourage treatment compliance in the Alzheimer's dementia setting.

This study is a single-arm, treatment-switched design. Eligible patients, who are under Exelon capsule 3 mg b. i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to patch for 48 weeks maintenance treatment. During the maintenance period, the treatment will be initiated with Exelon Patch 4. 6 mg/24 hours (Exelon Patch 5 cm2) for the first 24 weeks and the dose will be escalated to Exelon Patch 9. 5 mg/24 hours (Exelon Patch 10 cm2) for another 24 weeks if well tolerated. Visits to assess safety are scheduled at baseline, 3 days, 1 week and 2 weeks after the first treatment switch, every 4 weeks until Week 40, and at the end of study (Week 52). The assessment to address the primary objective will focus on the safety of treatment switching (Week 0~28); however the safety assessment will be performed during the whole study period.

more trials >>

Reports of Suspected Exelon (Rivastigmine) Side Effects

Death (309)Fall (124)Vomiting (86)Pneumonia (78)Cerebrovascular Accident (69)Malaise (63)Dementia Alzheimer's Type (63)Nausea (61)Somnolence (60)Confusional State (57)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Exelon has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Exelon review by 58 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   memory
Dosage & duration:   4.5 mg taken twice daily for the period of last 4 years or so
Other conditions:   depression
Other drugs taken:   lexapro namenda trileptal ambien
  
Reported Results
Benefits:   overall benefits were great. memory has not gotten worse and there is less frustration on my part. Makes my day much better. Although, I have peaks and lows...my lows have been better.
Side effects:   i did not find any side effects.
Comments:   the treatment was for slowing down the progression of memory loss. And it has!

See all Exelon reviews / ratings >>

Page last updated: 2014-09-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014